Published April 4, 2018 | Version v1
Dataset Open

Determining the plasticity of CD34 expression

Creators

  • 1. Structural Genomics Consortium, Princess Margaret Cancer Centre, University Health Network
  • 2. Structural Genomics Consortium, University of Toronto
  • 3. Princess Margaret Cancer Centre, University Health Network, University of Toronto
  • 4. Structural Genomics Consortium, Princess Margaret Cancer Centre, University Health Network, University of Toronto

Description

Determining if OCI-AML-20 cells can regain CD34 expression.

Notes

The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome [106169/ZZ14/Z]. This project receives funding from the Leukemia and Lymphoma Society of Canada.

Files

3-22-18_CD34_plasticity.pdf

Files (259.9 kB)

Name Size Download all
md5:b2635d91d60c361093256ea12b18ddc1
51.6 kB Download
md5:cdd2f7d03674a87bfebd7f5b41554c41
208.2 kB Preview Download